Expecto Health Science is pleased to announce that it has received the License to Operate as a Contract Research Organization (CRO) from the Philippines Food and Drug Administration (FDA). This approval marks a significant milestone in the companyโs strategic expansion across the Asia-Pacific (APAC) region.
With this license, Expecto Health Science is now authorized to conduct and manage global clinical trials in the Philippines, enabling sponsors to access high-quality, efficient, and fully compliant clinical research services in the region.
This achievement reflects the dedication of our experienced local team and the robustness of our global Quality Management System (QMS), which played a key role in the successful regulatory inspection and approval process.
This milestone strengthens our commitment to advancing clinical research across Asia and supporting improved patient access to innovative therapies
